37 Brain Cancer Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Brain Cancer Studies in New York

NCT02977780Recruiting

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib * Temozolomide (temodar) * Neratini...

New York, NYPHASE2460 participantsPatrick Wen, MD

View Study Details

NCT05271240Recruiting

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therap...

New York, NYPHASE3432 participantsNorthwell Health

View Study Details

NCT04081701Recruiting

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblas...

New York, NYPHASE4200 participantsWeill Medical College of Cornell University

View Study Details

NCT06991101Recruiting

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) fo...

New York, NYPHASE2190 participantsBaptist Health South Florida

View Study Details

NCT06458712Recruiting

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase....

New York, NYPHASE1180 participantsDuke Street Bio Ltd

View Study Details

NCT06805305Recruiting

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate...

New York, NYPHASE2180 participantsDiakonos Oncology Corporation

View Study Details

NCT04775485Recruiting

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying ...

New York, NYPHASE2141 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT00870129Recruiting

Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recu...

New York, NYNA135 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05559853Recruiting

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and grow...

New York, NY119 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05765812Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiothera...

New York, NYPHASE1116 participantsDebiopharm International SA

View Study Details

NCT07225621Recruiting

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy...

New York, NYPHASE2103 participantsAlpheus Medical, Inc.

View Study Details

NCT06816927Recruiting

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, a...

New York, NYPHASE292 participantsDuke University

View Study Details

NCT07282587Recruiting

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG)....

New York, NYPHASE290 participantsJazz Pharmaceuticals

View Study Details

NCT03213002Recruiting

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the t...

New York, NYPHASE167 participantsNorthwell Health

View Study Details

NCT05879367Recruiting

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluat...

New York, NYPHASE166 participantsOrbus Therapeutics, Inc.

View Study Details

NCT05419076Recruiting

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC....

New York, NYPHASE262 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06934889Recruiting

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in peo...

New York, NYPHASE160 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05188508Recruiting

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either...

New York, NYPHASE257 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT01269853Recruiting

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits th...

New York, NYPHASE154 participantsNorthwell Health

View Study Details

NCT06126744Recruiting

Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

This is a Phase 1 open label study designed to assess the safety and tolerability of the oncolytic herpes simplex virus 1 (oHSV1) study drug, MVR-C5252, administered intratumorally by convection-enhan...

New York, NYPHASE151 participantsDuke University

View Study Details

NCT07089641Recruiting

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade ...

New York, NYPHASE150 participantsJonsson Comprehensive Cancer Center

View Study Details

NCT05489783Recruiting

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry...

New York, NY50 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06829173Recruiting

Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas

This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O...

New York, NYEARLY_PHASE139 participantsNYU Langone Health

View Study Details

NCT02800486Recruiting

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survi...

New York, NYPHASE237 participantsNorthwell Health

View Study Details

NCT05303467Recruiting

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM....

New York, NYPHASE136 participantsBoston Scientific Corporation

View Study Details

NCT02861898Recruiting

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

New York, NYPHASE133 participantsNorthwell Health

View Study Details

NCT05954858Recruiting

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnos...

New York, NYNA32 participantsNorthwell Health

View Study Details

NCT07464925Recruiting

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteris...

New York, NYPHASE130 participantsTetragon Biosciences Ltd

View Study Details

NCT06058988Recruiting

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers t...

New York, NYPHASE230 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06712875Recruiting

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, ...

New York, NYPHASE127 participantsAnn & Robert H Lurie Children's Hospital of Chicago

View Study Details

NCT07223034Recruiting

A Study of 177Lu-PSMA-617 in People With Gliomas

The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma....

New York, NYPHASE120 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06807619Recruiting

A Study of Sotorasib in People With Brain Tumors

The researchers are doing this study to find out how effective sotorasib is at getting into KRAS G12C+ brain tumors. The researchers will also find out whether sotorasib is a safe and effective treatm...

New York, NYPHASE116 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05979064Recruiting

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multifo...

New York, NYNA10 participantsNorthwell Health

View Study Details

NCT05762419Recruiting

FUS Etoposide for DMG

The blood brain barrier (BBB) prevents some drugs from successfully reaching the target tumor. Focused Ultrasound (FUS) using microbubbles and neuro-navigator controlled sonication is a non-invasive m...

New York, NYPHASE110 participantsColumbia University

View Study Details

NCT06910306Recruiting

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma...

New York, NYNA10 participantsAlpha Tau Medical LTD.

View Study Details

NCT06666712Recruiting

Chronic CED of TPT for Recurrent Malignant Glioma

The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors...

New York, NYPHASE16 participantsJeffrey N. Bruce

View Study Details

NCT07530536Recruiting

rTMS for Postoperative Brain Tumor Patients

When doctors perform surgery to remove brain tumors, the goal is to take out as much of the tumor as possible while keeping the patient's brain functions intact. However, sometimes patients have troub...

New York, NYNA6 participantsBrian J.Gill

View Study Details

About Brain Cancer Clinical Trials in New York

Brain cancer includes tumors that originate in the brain (primary) or spread from other areas (metastatic). Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Treatment typically combines surgery, radiation, and chemotherapy, with immunotherapy trials underway.

There are currently 37 brain cancer clinical trials recruiting participants in New York, NY. These studies are seeking a combined 3,297 participants. Research is being sponsored by Patrick Wen, MD, Northwell Health, Weill Medical College of Cornell University and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Brain Cancer Clinical Trials in New York — FAQ

Are there brain cancer clinical trials in New York?

Yes, there are 37 brain cancer clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What brain cancer treatments are being tested?

The 37 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for brain cancer.

Data updated September 3, 2026 from ClinicalTrials.gov